NASDAQ · CSTL

Castle Biosciences, Inc.

Healthcare · Medical - Diagnostics & Research

$32.32▲ 0.03% ($0.01)at close

As of 4:00 PM ET

52-week

$17.72$44.28

Market cap

$987.36M

What the market price implies · Reverse DCF

Historical revenue grew by 38.3%/yr over the past 4 years.

Selected forecast · Base scenario

19.01%/yr · actual 10-year annualized revenue growth

Year 1 growth: 36.51%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$32.32

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Year 1 growth 36.51% · Ending margin 0% · Discount rate 10.34%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 2:06 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Mixed / unclearLow confidence

1Y Price: 40.89%Revenue (TTM): 3.18%FCF (TTM): -101.42%P/FCF: 55th pct

What changed

The stock rose 40.89% over the last year. Revenue grew 3.18% over the trailing twelve months. Operating margin moved from -6.66% to -8.99%. Free cash flow declined 101.42% over the trailing twelve months.

What the market seems to be pricing

The stock has moved higher against modestly weakening underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.

What would invalidate this read

Operating margin currently stands at -8.99%. A decisive move in revenue — currently up 3.18% — would be the clearest signal to resolve the ambiguity.

Performance

Return analysis

Company profile

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers.

CEODerek J. Maetzold

SectorHealthcare

IndustryMedical - Diagnostics & Research

Employees1,002

IPO dateJul 25, 2019

https://castlebiosciences.com

Market multiples

Forward P/E—

EV/EBITDA92.37

Enterprise value$1.05B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth20.14%

Gross margin77.26%▼2.5ppvs FY2024

Operating margin-8.99%▼15.0ppvs FY2024

ROE-4.2%▲1.0ppvs FY2025

Analyst consensus

RatingBuy

Target price$39.00▲20.67%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 2, 2026

Q4 FY26 · EPS est -$0.38 · Revenue est $92.13M

View